ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 1508 • ACR Convergence 2022

    Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging

    Siba Raychaudhuri1, Yasser Abdelhafez2, Dario Mazza3, Smriti Raychaudhuri4 and Abhijit Chaudhari3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, 2University of California Davis, Sacramento, CA, 3UC Davis, School of Medicine, Sacramento, CA, 4VA Medical Center, Sacramento, CA

    Background/Purpose: The enthesitis can be the earliest/primary inflammatory event in psoriatic arthritis (PsA). Clinically most of the entheses are not accessible and can't be assessed;…
  • Abstract Number: 1743 • ACR Convergence 2022

    Identification of Immune Cell Types in the Peripheral Blood of Rheumatoid Arthritis Patients Associated with Susceptibility and Response to Treatment

    Maria Christofi1, Ben Mulhearn2, Lysette Marshall1, Megan Sutcliffe1, Darren Plant1, Kimme Hyrich1, Ann Morgan3, Anthony Wilson4, John D Isaacs5, Soumya Raychaudhuri6, Anne Barton1 and Sebastien Viatte1, 1The University of Manchester, Manchester, United Kingdom, 2Royal United Hospital Bath | University of Bath, Bath, United Kingdom, 3University of Leeds, Leeds, United Kingdom, 4University College Dublin, Dublin, Ireland, 5Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a complex immune mediated disease that affects 1% of the population. Even with modern therapeutic strategies, many patients with RA…
  • Abstract Number: 1911 • ACR Convergence 2022

    Baseline Bone Curvature a Biomarker for the Prediction of Knee Osteoarthritis Cartilage Volume Loss at One-Year. Use of Machine Learning

    Johanne Martel-Pelletier1, Hossein Bonakdari1, Jean-Pierre Pelletier1 and François Abram2, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montréal, QC, Canada, 2ArthroLab Inc., Montréal, QC, Canada

    Background/Purpose: The hallmark of osteoarthritis is the loss of cartilage. At present, we cannot discriminate, early during the osteoarthritis process, patients for whom cartilage will…
  • Abstract Number: 2129 • ACR Convergence 2022

    Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

    Signe Holm Nielsen1, Anne-Christine Bay-Jensen1, Peder Frederiksen1, Morten Karsdal1, May Shawi2, Soumya Chakravarty3, Alexa Kollmeier4, Warner Chen5 and Sheng Gao5, 1Nordic Bioscience, Herlev, Denmark, 2Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 3Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 4Janssen-Cilag, Research & Development, LLC, San Diego, CA, 5Janssen Research and Development, LLC, Spring House, PA

    Background/Purpose: Psoriatic arthritis (PsA) is a progressive, joint-degenerative inflammatory disease with cartilage destruction, bone erosion and growth, and synovitis. Extracellular matrix (ECM) remodeling is also…
  • Abstract Number: 0040 • ACR Convergence 2022

    Plasma Proteomic Signatures in Juvenile Dermatomyositis Highlight Novel Proteins and a Protein Module That Associate with Skin and Global Disease Activity

    Marianne Kerski1, Celine Berthier1, Alex Tsoi1, Sarah Vandenbergen1, Madison McClune1, Corey Powell1, J. Michelle Kahlenberg1 and Jessica Turnier2, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Saline, MI

    Background/Purpose: Juvenile dermatomyositis (JDM) patients display heterogenous disease phenotypes and treatment response patterns. Our study used a multiplexed proteomics assay for measurement of 3072 proteins…
  • Abstract Number: 0333 • ACR Convergence 2022

    Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis

    Andrea Fava1, Carla J. Guthridge2, Joseph Kheir2, Catriona Wagner3, Michelle Petri4, Jill Buyon5, Betty Diamond6, the Accelerating Medicines Partnership (AMP) RA/SLE7, Joel Guthridge2 and Judith James2, 1Johns Hopkins University, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma, 4Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 5NYU Grossman School of Medicine, New York, NY, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Multiple Insitutions

    Background/Purpose: Autoantibodies are a hallmark of lupus nephritis (LN). While there is known heterogeneity in autoantibody expression among LN patients, the association of autoantibodies with…
  • Abstract Number: 0587 • ACR Convergence 2022

    Increase of Intercellular Adhesion Molecule-1 Linked to Lung Damage of Interstitial Lung Disease in Patients with Autoimmune Diseases

    Veronica Pulito-Cueto1, Sara Remuzgo-Martinez1, Fernanda Genre1, Belén Atienza-Mateo1, David Iturbe-Fernández1, Víctor M. Mora-Cuesta1, Leticia Lera-Gómez1, Diana Prieto-Peña1, Virgi Portilla1, Ricardo Blanco2, Oreste Gualillo3, Alfonso Corrales1, José M. Cifrián1, Raquel Lopez Mejias4 and Miguel Ángel González-Gay5, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, 4IDIVAL, Santander, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Intercellular adhesion molecule-1 (ICAM-1) regulates leukocyte recruitment from circulation to sites of inflammation, being considered as a marker of underlying endothelial damage [1]. Moreover,…
  • Abstract Number: 0811 • ACR Convergence 2022

    Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction

    Yael Ross1 and Stanley Ballou2, 1Case Western Reserve University at MetroHealth Medical Center, Atlanta, GA, 2Case Western Reserve University - Metro Health, Cleveland, OH

    Background/Purpose: C-reactive protein (CRP) is an acute-phase reactant widely employed clinically as a marker of inflammation. Serum CRP level is generally elevated with any type…
  • Abstract Number: 1002 • ACR Convergence 2022

    Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the S1P1 Receptor Modulator Cenerimod

    Daniel Strasser1, clélia Cahuzac2, peter Cornelisse2, Ouali Berkani2, Peter Groenen2 and Mark Murphy2, 1Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, 2Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland

    Background/Purpose: Sphingosine-1-phosphate (S1P) regulates lymphocyte egress from lymphoid organs into circulation. In a SLE proof-of-concept study, cenerimod—a potent, selective S1P1 receptor modulator—reduced circulating antibody-secreting cells…
  • Abstract Number: 1333 • ACR Convergence 2022

    Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry

    William Nowell1, Shilpa Venkatachalam2, Kelly Gavigan1, Michael George3, Johanna Withers4, Laura Stradford5, Esteban Rivera1 and Jeffrey Curtis6, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Global Healthy Living Foundation, New York, NY, 3University of Pennsylvania, Philadelphia, PA, 4Scipher Medicine Corportaion, Waltham, MA, 5Global Healthy Living Foundation, Nyack, NY, 6Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Although patients' (pts) perspective on disease-related lab testing and its role in treatment decision-making has been examined for some chronic illnesses, ranging from diabetes…
  • Abstract Number: 1517 • ACR Convergence 2022

    Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain

    Nelly Ziade1, Avin Maroof2, Antonella Abi Najm1, Torsten Witte3 and Xenofon Baraliakos4, 1Saint-Joseph University, Beirut, Lebanon, 2Rizgary Teaching Hospital - Erbil, Erbil, Iraq, 3MH-Hannover, Hannover, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) are diagnosed late, partially due to the absence of a reliable biomarker. The diagnostic value of the anti-CD74 antibodies…
  • Abstract Number: 1746 • ACR Convergence 2022

    Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response

    María-Eugenia Miranda-Carús1, Alejandro Villalba1, Laura Nuño1, Marta Benito-Miguel2, Irene Monjo1, Marta Novella-Navarro1, Diana Peiteado1, Sara Garcia-Carazo1 and Alejandro Balsa3, 1Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, 2Universidad Nebrija, Physiology, Madrid, Spain, 3Hospital La Paz Institute for Health Research, Madrid, Spain

    Background/Purpose: FoxP3+ regulatory CD4+ T cells (Tregs) are key to the homeostasis of the immune system. Stressed cells at inflammatory foci release adenine nucleotides to…
  • Abstract Number: 1914 • ACR Convergence 2022

    Acoustic Classification of Early and Advanced Osteoarthritis of the Knee in Clinical Settings

    Dave Ewart1, Ashley Draisey2, Omer Inan3, Chris Nichols3 and Goktug Ozmen3, 1Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, 2Allina Health, Minneapolis, MN, 3Georgia Institute of Technology, Atlanta, GA

    Background/Purpose: Knee osteoarthritis (OA) is a prevalent and debilitating disease. Diagnosis of early knee OA is difficult and insensitive with current technologies. The human knee…
  • Abstract Number: 2135 • ACR Convergence 2022

    Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis

    James C Waddington1, Ruoyi Zhou1, Orla Coleman1, Bruna Wundervald2, Andrew Parnell3, Vinod Chandran4, Lara Fallon5, Douglass Chapman6, Remy Pollock7, Shibing Deng8, Oliver FitzGerald9, Stephen R Pennington10 and Philip J Mease11, 1Atturos, Dublin, Ireland, 2Atturos/Hamilton Institute, Maynooth University, Dublin, Ireland, 3Hamilton Institute, Maynooth University, Kildare, Ireland, 4Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 5Pfizer Inc, Montréal, QC, Canada, 6Pfizer Inc, New York, NY, 7Pfizer Canada ULC, Kirkland QC, Canada, 8Pfizer Inc, Waterford, MI, 9Conway Institute, University College Dublin, Dublin, Ireland, 10Atturos/Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 11Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.1,2 Using two mass spectrometry (MS)-based proteomic approaches (targeted multiple reaction monitoring [MRM]…
  • Abstract Number: 0043 • ACR Convergence 2022

    Non-invasive Tape Strip Gene Expression Profiling of Lesional Juvenile Dermatomyositis Skin Identifies Immunoregulatory Module That Associates with Skin, Muscle and Global Disease Activity

    Jessica Turnier1, Celine Berthier2, Madison McClune2, Sarah Vandenbergen2, Johann Gudjonsson2, Alex Tsoi2 and J. Michelle Kahlenberg2, 1University of Michigan, Saline, MI, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) frequently persists even in the absence of active muscle disease. Tape stripping is a non-invasive skin sampling method…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology